《2011NICE肺癌診治指南》內(nèi)容簡介:
Since publication of NICE clinical guideline 24 in 2005, a number of newsystemic therapies have been granted a marketing authorisation by theEuropean Medicines Agency for use in people with NSCLC. NICE haspublished technology appraisals for pemetrexed, gefitinib and erlotinib. Othertechnology appraisals are in development.
《2011NICE肺癌診治指南》內(nèi)容預覽:
This guidance updates and replaces NICE clinical guideline 24 (publishedFebruary 2005)。
New and updated recommendations are included on communication,diagnosis and staging, selection of patients with non-small-cell lung cancer(NSCLC) for treatment with curative intent, surgery with curative intent forNSCLC, smoking cessation, combination treatment for NSCLC, treatment forsmall-cell lung cancer (SCLC), managing endobronchial obstruction,managing brain metastases, and follow-up and patient perspectives.
點擊下載***:《2011NICE肺癌診治指南》
本共識意見(草案)依據(jù)我國胰腺囊性腫瘤的最近研究,并參考國際相關指南和研究...[詳細]
在美國,結直腸癌發(fā)病率占所有癌癥的第四位,而死亡率為第二位。2012年估計...[詳細]